GlassScriptPhysician profile
Olga C Aroniadis
NPI 1942508262
$4,071.66
in general payments reported to CMS, 2019-2025
25 companies · $1,203 in 2025
The $1,203 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.35 · 2021: $205 · 2022: $610 · 2023: $670 · 2024: $1,345 · 2025: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,189 · Education: $29.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,188.90 |
| Education | $29.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,505.19 | 2021-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $490.53 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Medtronic, INC. | $317.10 | 2024 | Signia |
| Olympus America INC. | $266.12 | 2025 | Single Use Repositionable Clip, Single Use Biliary Balloon Dilator, Endoclot Sis |
| Steris Corporation | $237.77 | 2021-2024 | |
| Boston Scientific Corporation | $217.83 | 2023-2025 | Axios, Varithena Administration Pack |
| Ardelyx, INC. | $157.64 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $124.22 | 2020-2025 | Gattex, Entyvio, Eohilia |
| Lilly USA, LLC | $94.45 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $90.24 | 2023-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $86.55 | 2022-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $77.84 | 2024 | Voquezna |
| Cook Medical LLC | $73.02 | 2024 | Zenith Spiral-Z |
| Endogastric Solutions, INC | $54.68 | 2024 | Esophyx |
| Merck Sharp & Dohme LLC | $46.60 | 2022-2024 | Dificid |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $42.64 | 2024 | Givlaari |
| Mallinckrodt Hospital Products INC. | $32.30 | 2024 | Terlivaz |
| Celltrion USA INC. | $29.12 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $27.26 | 2025 | Iqirvo |
| Novo Nordisk INC | $25.01 | 2025 | Wegovy |
| Lucid Diagnostics INC. | $24.32 | 2022 | |
| Mirum Pharmaceuticals, INC. | $19.36 | 2025 | |
| Genzyme Corporation | $18.37 | 2024 | |
| Celgene Corporation | $13.50 | 2023 | Zeposia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Aroniadis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.